top of page

KLUS Pharma is Attending BIO International Convention Digital Event

KLUS Pharma will attend BIO Digital 2021 from June 14-18. As the US subsidiary of Kelun-Biotech, a top 10 pharma in China, we have built up an extensive pipeline of small molecules and biologics to address unmet needs in cancer and other serious diseases. Check out the showcase for our innovative ADC platform during BIO week:

Link to presentation:

In addition, we are seeking partnerships involving licensing or co-development strategies to advance innovative small molecules and biologic drugs for cancer. Other areas of interest may include autoimmune disease, metabolic disease, liver disease (NASH/HBV) and clotting disorders. We are mainly seeking research and technologies in the following areas:

-Antibody-Drug Conjugate (ADC) technologies and inventions
-Therapeutic bispecific antibodies or technology platforms
-First-in-class targets for oncology, especially in the tumor microenvironment
-Fc function enhancement technologies
-Off-the-shelf cell therapies with potential to treat solid tumors
-First-in-class or best-in-class small molecules with preliminary efficacy data

We are also actively looking for potential partners with strong clinical and commercialization teams to further advance our internal pipeline. We are excited to connect with potential partners during the upcoming BIO Digital virtual event and welcome interested parties to message us.

Business Development, KLUS Pharma

Thursday, May 20, 2021

bottom of page